Cargando…

Telaprevir combination therapy in HCV/HIV co-infected patients (INSIGHT study): sustained virologic response at 12 weeks final analysis

INTRODUCTION: We report the SVR12 final analysis of a phase 3 study of telaprevir in combination with peginterferon (P)/ribavirin (R) in HCV-genotype 1, treatment-naïve and -experienced patients with HCV/HIV co-infection (INSIGHT). MATERIALS AND METHODS: Patients receiving stable, suppressive HIV an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Montes, Marisa, Nelson, Mark, Marie Girard, Pierre, Sasadeusz, Joe, Horban, Andrzej, Grinsztejn, Beatriz, Zakharova, Natalia, Rivero, Antonio, Lathouwers, Erkki, Janssen, Katrien, Ouwerkerk-Mahadevan, Sivi, Witek, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P094
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224845/ https://www.ncbi.nlm.nih.gov/pubmed/25394130 http://dx.doi.org/10.7448/IAS.17.4.19626

Ejemplares similares

Efficacy and tolerability of telaprevir (TVR)-based triple therapy in HIV/HCV-coinfected patients
por: De Los Santos, Ignacio, et al.
Publicado: (2014)

BIOSSEGURANÇA ENTRE MÉDICOS DOCENTES DE UM CURSO DE MEDICINA DE JOÃO PESSOA‐PB: DO CONHECIMENTO À PRÁTICA
por: Lopes, Aline Morais, et al.
Publicado: (2021)

CARACTERÍSTICAS EPIDEMIOLÓGICAS DA SEPSE NAS UNIDADES DE SAÚDE PÚBLICA NO BRASIL ENTRE OS ANOS DE 2018 E 2021: IMPACTO DA PANDEMIA DE COVID-19
por: Júnior, José Geraldo Santos de Lima, et al.
Publicado: (2022)

Le diabète : facteur associé à la gravité de la maladie COVID-19 avec le variant omicron sur le territoire du Centre-Est tunisien
por: Mbarek, R., et al.
Publicado: (2022)

Monitoring renal function during combination therapy with telaprevir in HIV/HCV co-infected patients with advanced/fibrosis cirrhosis
por: Puzzolante, Cinzia, et al.
Publicado: (2014)

Telaprevir or boceprevir in HIV/HCV-1 co-infected patients in a real-life setting. Interim analysis (24 weeks). COINFECOVA-SEICV study
por: Minguez, Carlos, et al.
Publicado: (2014)

Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study
por: Borba, Helena HL, et al.
Publicado: (2017)

Analysis of hepatitis non-treatment causes in a cohort of HCV and HCV/HIV infected patients
por: Pereira, Karen, et al.
Publicado: (2014)

Liver Fibrosis progression using Fibroscan in HIV/HCV coinfected patients with undetectable HIV viral load
por: Perez-Martinez, Laura, et al.
Publicado: (2014)

HCV triple therapy in co-infection HIV/HCV is not associated with a different risk of developing major depressive disorder
por: Fialho, Renata, et al.
Publicado: (2014)

Safety analysis of raltegravir/truvada regimen in HIV/HCV co-infected patients without switchback after HCV treatment
por: Ehret, Robert, et al.
Publicado: (2014)

Improve screening of HCV infection by targeting high prevalence aged groups: analysis of a cohort of HCV and HIV co-infected patients
por: Brogueira, Pedro, et al.
Publicado: (2014)

Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression
por: Carbone, Alessia, et al.
Publicado: (2014)

Telaprevir
Publicado: (2012)

Appearance of NS3 Q80K mutation in HCV genotype 1a mono- or HIV/HCV co-infected patients in a Berlin laboratory
por: Ehret, Robert, et al.
Publicado: (2014)

Detection of resistance mutations and CD4 slopes in individuals experiencing sustained virological failure
por: Schultze, Anna, et al.
Publicado: (2014)

Time to virologic failure for patients taking their first antiretroviral regimen and the subsequent resistance profiles
por: Crouzat, Frederic, et al.
Publicado: (2014)

The suspected unexpected and serious adverse events of antiretroviral drugs used as HIV prophylaxis in HIV uninfected persons
por: Pietraszkiewicz, Ewa, et al.
Publicado: (2014)

Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study
por: Neukam, Karin, et al.
Publicado: (2014)

The effects of Maraviroc on liver fibrosis in HIV/HCV co-infected patients
por: Ortega Gonzalez, Enrique, et al.
Publicado: (2014)

Boceprevir (BOC) and Telaprevir (TPV) therapeutic drug monitoring in HCV and HIV-HCV infected patients treated with triple therapy Ribavirine/Peg-interferon/Boceprevir or Telaprevir: impact of the antiretroviral (ARV) treatment
por: Chantry, AS, et al.
Publicado: (2014)

Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir
por: De Meyer, Sandra, et al.
Publicado: (2014)

Use of dolutegravir in two INI-experienced patients with multiclass resistance resulted in excellent virological and immunological responses
por: Marije Hofstra, Laura, et al.
Publicado: (2014)

Resistance mutations in protease gene at baseline are not related to virological failure in patients treated with darunavir/ritonavir monotherapy
por: Gutierrez-Liarte, Angela, et al.
Publicado: (2014)

Simplification to co-formulated rilpivirine/emtricitabine/tenofovir in virologically suppressed patients: Data from a multicenter cohort
por: Pinnetti, Carmela, et al.
Publicado: (2014)

Clinical and socio-demographic predictors for virologic failure in rural Southern Africa: preliminary findings from CART-1
por: Daniel Labhardt, Niklaus, et al.
Publicado: (2014)

A retrospective observational study of low-level viraemia and its immunological and virological significance: which outcome to expect
por: Silva, Joana, et al.
Publicado: (2014)

Difference in factors associated with low-level viraemia and virological failure: results from the Austrian HIV Cohort Study
por: Leierer, Gisela, et al.
Publicado: (2014)

Switching from ritonavir to cobicistat in HIV patients with renal impairment who are virologically suppressed on a protease inhibitor
por: Fisher, Martin, et al.
Publicado: (2014)

Drug–Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir
por: Ouwerkerk-Mahadevan, Sivi, et al.
Publicado: (2015)

Screening for HCV infection combined with SARS-CoV-2 vaccination in the Campania region
por: Torre, P., et al.
Publicado: (2022)

Effect of HIV infection-related factors on SVR rate in HCV treatment in HIV-infected patients
por: Kravchenko, Alexey, et al.
Publicado: (2014)

The absolute lymphocyte count accurately estimates CD4 counts in HIV-infected adults with virologic suppression and immune reconstitution
por: Young, Barnaby, et al.
Publicado: (2014)

Renal safety profile of STB in virologically suppressed subjects from two randomized phase 3b switch trials
por: Reeves, Iain, et al.
Publicado: (2014)

Acute HIV infection (AHI) in a specialized clinical setting: case-finding, description of virological, epidemiological and clinical characteristics
por: Ammassari, Adriana, et al.
Publicado: (2014)

Socio-economic factors and virological suppression among people diagnosed with HIV in the United Kingdom: results from the ASTRA study
por: Burch, Lisa, et al.
Publicado: (2014)

Alarming increase in tuberculosis and hepatitis C virus (HCV) among HIV infected intravenous drug users
por: Oprea, Cristiana, et al.
Publicado: (2014)

Evaluation of the degree of liver fibrosis and genetical characteristics in HIV patients with spontaneous clearance of HCV in Cartagena, Spain
por: Jesús Vera Méndez, Francisco, et al.
Publicado: (2014)

Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort
por: Saracino, Annalisa, et al.
Publicado: (2014)

Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression
por: Llibre, Josep M, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_unlqg9t919e4bqqjulrte5mona